Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells

Autor:	Jill E. Kucab, Sandra E. Dunn, Golerah Habibi, Heather N. Andrews
Rok vydání:	2005
Předmět:	MAPK/ERK pathway Cancer Research medicine.medical_specialty Breast Neoplasms Breast cancer Internal medicine Cell Line Tumor medicine Humans Cyclooxygenase Inhibitors Viability assay RNA Messenger skin and connective tissue diseases Protein kinase B Cell Proliferation Urokinase Mitogen-Activated Protein Kinase 1 Sulfonamides Mitogen-Activated Protein Kinase 3 biology Dose-Response Relationship Drug medicine.disease Urokinase-Type Plasminogen Activator Endocrinology Oncology Enzyme inhibitor Celecoxib biology.protein Cancer research Pyrazoles Plasminogen activator Proto-Oncogene Proteins c-akt medicine.drug Signal Transduction
Zdroj:	Breast cancer research and treatment. 94(1)
ISSN:	0167-6806
Popis:	Elevated urokinase-type plasminogen activator (uPA) expression in breast tumors predicts poor survival. We found celecoxib (25 microM) significantly reduced uPA protein and mRNA in MDA-MB-231 breast cancer cells following 72 h of treatment. Celecoxib also inhibited cell viability (12.5 and 25 microM) and induced G2M arrest (25 microM). Therefore, celecoxib therapy for uPA positive breast cancer should be explored.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90282af103b8e0c5e234c560fc1f3695 https://pubmed.ncbi.nlm.nih.gov/16172791 Zobrazit plný text záznamu Full text from SpringerLink